Abstract
Objective KBP-5074 is a novel non-steroidal mineralocorticoid receptor antagonist for the potential treatment of hypertension. The purpose of this study was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of 0.5 mg KBP-5074 in subjects with end stage renal disease on and not on hemodialysis.
Results Single doses of 0.5 mg KBP-5074 were generally well tolerated in both hemodialysis (N=6) and non-hemodialysis (N=5) subjects with severe renal impairment. Of the 11 subjects in the study, there was a single report of hyperkalemia in a hemodialysis subject on Day 14 that was not considered drug-related and was resolved in 2 days. Mean plasma KBP-5074 concentrations peaked at 6 and 4 hours in non-dialysis and dialysis subjects, respectively, and slowly declined through 312 hours postdose. Overall, the KBP-5074 exposures were significantly lower and had a shorter half-life in hemodialysis subjects compared with the non-hemodialysis subjects. However, hemodialysis had minimal direct impact on drug concentrations with negligible drug levels in the dialysate samples. Plasma aldosterone and serum potassium concentrations were generally comparable between non-hemodialysis and hemodialysis subjects, most likely to due to high variability in the hemodialysis subjects.
Conclusion The overall plasma exposure of KBP-5074 was statistically significantly lower in hemodialysis subjects compared to subjects with renal impairment not on hemodialysis.
Competing Interest Statement
VB, JL, XT, PW, TZ, MZ and FY are employees of KBP Biosciences. JC was the principal investigator and JR was the medical monitor of the study who received funding from KBP Biosciences for their involvement with the clinical conduct of the study. MB provided analytical support and was an employee of Wingate University School of Pharmacy at the time.
Clinical Trial
NCT02837237
Funding Statement
This study was fully supported by KBP Biosciences Co. Ltd.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Acknowledgements The study was funded by KBP BIOSCIENCES CO., LTD. We thank the participation of the local principal investigators and staff at the study sites. All authors reviewed drafts of the manuscript, approved the final version and agree to be accountable for the work. Medical writing support was provided by Guissou Dabiri, PhD of GD Scientific & Medical Writing, LLC and was funded by KBP Biosciences.
Conflict of Interest VB, JL, XT, PW, TZ, MZ and FY are employees of KBP Biosciences. JC was the principal investigator and JR was the medical monitor of the study who received funding from KBP Biosciences for their involvement with the clinical conduct of the study. MB provided analytical support and was an employee of Wingate University School of Pharmacy at the time.
Ethical Approval The study was approved on 17 May 2016 by IntegReview IRB, 3815 S. Capital of Texas Highway, Suite 320, Austin, TX 78704
Data Availability
All data resides in the trial master file maintained by KBP Biosciences Co. Ltd.
